Scarica l'app Stockscreener
9.00
0.44%
-0.04
Pre-mercato:
9.09
0.09
+1.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GRFS Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$9.04
Aprire:
$8.91
Volume 24 ore:
246.98K
Relative Volume:
0.30
Capitalizzazione di mercato:
$6.14B
Reddito:
$7.94B
Utile/perdita netta:
$225.54M
Rapporto P/E:
27.28
EPS:
0.3299
Flusso di cassa netto:
$709.16M
1 W Prestazione:
+5.39%
1M Prestazione:
+8.30%
6M Prestazione:
+20.97%
1 anno Prestazione:
+43.31%
Intervallo 1D:
$8.90
$9.10
Intervallo di 1 settimana:
$8.44
$9.10
Portata 52W:
$6.19
$9.96
Grifols Sa Adr Stock (GRFS) Company Profile
Nome
Grifols Sa Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GRFS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
9.00 | 6.14B | 7.94B | 225.54M | 709.16M | 0.3299 |
|
LLY
Lilly Eli Co
|
775.90 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.92 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
69.82 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
189.99 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
123.10 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-12 | Ripresa | Morgan Stanley | Overweight |
| 2024-03-12 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-04-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-16 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2023-01-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-04-08 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-11-05 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-10-19 | Downgrade | Barclays | Overweight → Underweight |
| 2021-10-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-06-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2021-04-20 | Iniziato | Deutsche Bank | Hold |
| 2021-03-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-03-11 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2020-10-01 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-06-09 | Downgrade | Citigroup | Neutral → Sell |
| 2020-06-09 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2020-03-25 | Downgrade | Citigroup | Buy → Neutral |
| 2019-06-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-02-08 | Downgrade | Berenberg | Buy → Hold |
| 2018-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2018-06-01 | Iniziato | Barclays | Overweight |
| 2017-10-31 | Iniziato | Citigroup | Buy |
| 2017-06-30 | Downgrade | Goldman | Buy → Neutral |
| 2017-04-06 | Iniziato | BofA/Merrill | Buy |
| 2017-01-03 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-02-09 | Aggiornamento | Berenberg | Hold → Buy |
| 2016-01-04 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2015-12-02 | Downgrade | HSBC Securities | Buy → Hold |
| 2015-11-20 | Downgrade | Berenberg | Buy → Hold |
| 2015-04-28 | Downgrade | Berenberg | Buy → Hold |
Mostra tutto
Grifols Sa Adr Borsa (GRFS) Ultime notizie
ADMA Biologics Vs. Grifols: Which Plasma Therapy Stock Is The Better Buy? - Barchart.com
Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha
Grifols S.A. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
SMRT’s latest rating updates from top analysts. - knoxdaily.com
Investing in Grifols SA ADR (GRFS): What You Must Know - knoxdaily.com
Investing in Apellis Pharmaceuticals Inc (APLS) Is Getting More Attractive - knoxdaily.com
A company insider recently sold 10,000 shares of News Corp [NWSA]. Should You also Consider to Sale? - knoxdaily.com
Raymond James Downgrades Truist Financial Corporation (TFC) to a Mkt perform from an Outperform - knoxdaily.com
AT&T, Inc (T) rating upgrades by Exane BNP Paribas - knoxdaily.com
Grifols SA ADR (GRFS) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Lazard Inc (LAZ) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Can Verra Mobility Corp Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
RYAN’s Market Whiplash: 0.32% YTD Rise, -10.03% Plunge in 30 Days - investchronicle.com
A significant driver of top-line growth: Grifols SA ADR (GRFS) - Sete News
SpringWorks Therapeutics Inc (SWTX) Stock: From Low to High in 52 Weeks - investchronicle.com
There is no doubt that Coeur Mining Inc (CDE) ticks all the boxes. - Sete News
GRFS (Grifols SA ADR) may reap gains as insiders became active recently - knoxdaily.com
BHP’s latest rating updates from top analysts. - knoxdaily.com
FHN’s latest rating updates from top analysts. - knoxdaily.com
Lake Street’s latest rating for ORGO stock - knoxdaily.com
Fox Corporation [FOX] stock was sold by MURDOCH KEITH RUPERT at the price of US$3.08 million - knoxdaily.com
6 undervalued stocks with low beta - Morningstar
Deutsche Bank raises Grifols SA price target to EUR11.00 - Investing.com India
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Get in on Grifols SA ADR’s (GRFS) buy-in window today! - SETE News
Wall Street analysts’ outlook for Douglas Elliman Inc (DOUG) - SETE News
Financial Metrics Exploration: Understanding Accuray Inc (ARAY) Through Ratios - The Dwinnex
Financial Fitness Check: Examining Mannkind Corp (MNKD)’s Key Ratios - The Dwinnex
Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.
Grifols: More Attractive Than In A Very Long Time (NASDAQ:GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance
Brookfield Drops $6.8 Billion Offer to Buy Drugmaker Grifols - BNN Bloomberg
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance
Grifols stock slips as Brookfield offer rebuffed (GRFS:NASDAQ) - Seeking Alpha
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
UK Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
The UAE Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
Grifols shares up on potential takeover by Brookfield - Investing.com
China Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
India Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Grifols, S.A. (BME:GRF) most popular amongst retail investors who own 45% of the shares, institutions hold 35% - Simply Wall St
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks - Morningstar
Grifols sees China stake sale going ahead despite Gotham City report - Reuters
BreakingviewsShort attack intensifies Grifols’ health problem - Reuters
Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients - PR Newswire UK
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 - PR Newswire
Grifols Sa Adr Azioni (GRFS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):